Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
December 27, 2017Third clinical research site for NRX-100 / NRX-101 phase 2B/3 clinical studyNeuroRx, a clinical stage biopharma company developing the first drug regimen to treat severe bipolar depression in patients with Acute Suicidal Ideation and Behavior (ASIB), announced that it has...
-
September 6, 2017Company to present at Rodman and Renshaw Global Investment Conference in New York City on Sept 12, 2017
NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track status by the US Food and Drug...
-
April 12, 2017Recent hospitalization is a risk factor for further suicide attempts -- potentially related to patient care perceptions
WILMINGTON, Del. - NeuroRx launches the first global “Voice of the Patient Survey” for those diagnosed with bipolar disorder, in collaboration with leading patient advocacy groups, mental...
-
March 24, 2017Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression
Wilmington, Delaware , March 24, 2017 -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that...
-
March 19, 2017Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression
Wilmington, Delaware , March 20, 2017 -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that...
Click here to view our corporate presentation or on the image below
 |
